Updated
Reviewed
Jun. 03, 2021

Appendix B: Drug Characteristics Tables

Characteristics of the gp120 Attachment Inhibitor

Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Serum Half-Life Elimination/ Metabolic Pathway Adverse Events
Fostemsavir
(FTR)
Rukobia
  • 600-mg extended-release tablets
  • FTR 600 mg PO twice daily
11 hours Hydrolysis (esterases), CYP3A4

Nausea 

QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval.

Transaminase elevation; transient bilirubin elevation

Sleep disturbance, dizzines

Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Appendix B: Drug Characteristics Tables

Characteristics of the gp120 Attachment Inhibitor

Appendix B, Table 10. Characteristics of the gp120 Attachment Inhibitor
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Serum Half-Life Elimination/ Metabolic Pathway Adverse Events
Fostemsavir
(FTR)
Rukobia
  • 600-mg extended-release tablets
  • FTR 600 mg PO twice daily
11 hours Hydrolysis (esterases), CYP3A4

Nausea 

QTc prolongation was seen at 4 times the recommended dose. Use with caution in patients with preexisting heart disease, QTc prolongation, or concomitant use of medications that may prolong QTc interval.

Transaminase elevation; transient bilirubin elevation

Sleep disturbance, dizzines

Key: CYP = cytochrome P; FTR = fostemsavir; PO = orally; QTc = corrected QT interval

Download Guidelines